NDAORALSUSPENSION
Approved
Jan 2016
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
READI-CAT 2 SMOOTHIE (barium sulfate) by Bracco is x-ray contrast activity [moa]. Approved for radiographic contrast agent [epc]. First approved in 2016.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
READI-CAT 2 SMOOTHIE is an oral barium sulfate suspension approved in 2016 for use as a radiographic contrast agent. It enables visualization of the gastrointestinal tract during X-ray imaging by absorbing radiation. The product is designed for patient convenience with a smoothie formulation that improves palatability compared to traditional barium preparations.
Peak
Peak lifecycle product with moderate competitive pressure (30%), indicating stable commercial operations and mature team structures focused on maintenance and market defense.
Mechanism of Action
X-Ray Contrast Activity
Pharmacologic Class:
Radiographic Contrast Agent
Indications (1)
Career Relevance
Working on READI-CAT 2 SMOOTHIE offers career value in diagnostic imaging and specialty pharmaceutical marketing within a mature, profitable product portfolio. Team members typically develop expertise in niche contrasting markets, healthcare system relationships, and operational efficiency—skills valuable across diagnostic and specialty pharma sectors.
Worked on READI-CAT 2 SMOOTHIE at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.